EXOG

Across TCGA pan-cancer cohorts, EXOG mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EXOG data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EXOG mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EXOG expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where EXOG mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.271	0.440	.017	5	view →
CCRCC	DFS	Quartile	III,IV	0.074	0.904	.017	3	view →
UCEC	DFS	Tertile	All	0.811	0.973	.029	2	view →
LSCC	DFS	Quartile	All	0.366	0.912	.031	2	view →
HNSC	DFS	Median	II,III,IV	0.850	0.719	.039	2	view →
GBM	OS	Tertile	All	0.903	0.751	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EXOG–PDAC (DFS)

Open the PDAC breakdown →